Pulmonx reports Q1 EPS (36c), consensus (40c)

Reports Q1 revenue $22.54M, consensus $22.03M. “We are off to a strong start in 2025 as we continue to advance our Acquire, Test, and Treat strategy to broaden patient access to Zephyr Valves,” said Steve Williamson, president and CEO. “We delivered solid performance and early momentum from our commercial initiatives underscores the strength of our long-term growth strategy. With our focused execution plan, growing global presence, and continued innovation, we believe Pulmonx (LUNG) is well-positioned to deliver sustained growth and create long-term value for our shareholders.”